PCP becomes Diagnos minority investor at close of Warnex merger
Canadian healthcare-focused private equity firm Persistence Capital Partners (PCP) has become a minority shareholder in Diagnos Inc (TSXV: ADK) following the completion of Diagnos' merger with Warnex Inc, a PCP portfolio company. PCP has assumed a 13.76 percent interest in Diagnos, which is a Brossard, Québec-based provider of data mining and consulting services and a designer of data analytics software for healthcare and natural resources industries. PCP also holds warrants to purchase common shares of the company. Based in Montréal, PCP is currently raising its second fund, Persistence Capital Partners II LP.
11 July 2014•2 mins read
